CHMP recommends EU approval of Roche’s Vabysmo, the first bispecific antibody for the eye, for two leading causes of vision loss July 22, 2022July 30, 2022 by / Share This.....LinkedinTwitterFacebookGoogleEmailRelated News: FDA approves Roche’s Vabysmo, the first bispecific…FDA approves Roche’s Vabysmo, the first bispecific…European Commission approves Roche’s Vabysmo, the…New two-year data for Roche’s Vabysmo and Susvimo…New two-year data for Roche’s Vabysmo and Susvimo…The Lancet publishes studies showing Roche’s…
